Adherence to low molecular weight heparin treatment by patients with cancer who develop VTE
Adherence to low molecular weight heparin treatment by patients with cancer who develop VTE
Patients with cancer who are diagnosed with venous thromboembolism (VTE) are managed with low molecular weight heparin (enoxaparin), an established treatment. Those with incidental VTE are generally stable and can be treated as outpatients, and their knowledge and ability to self-administer injections contributes to treatment adherence. However, the limited, or absence of, signs and symptoms associated with incidental VTE can affect adherence. This article reports the results of an audit that examined patients’ understanding of VTE, and the information they receive from healthcare professionals to support self-management. The audit found there is a difference in adherence between patients with incidental VTE and those who have symptomatic events. Results demonstrate the need for written information and a clear management pathway.
21-26
Diez de los Rios de la Serna, Celia
92f2f698-de0c-42e4-a8f3-94c8ef49338e
Richardson, Alison
3db30680-aa47-43a5-b54d-62d10ece17b7
Lennan, Elaine
3197869c-1e29-4c7e-94cc-7dc896044216
10 May 2017
Diez de los Rios de la Serna, Celia
92f2f698-de0c-42e4-a8f3-94c8ef49338e
Richardson, Alison
3db30680-aa47-43a5-b54d-62d10ece17b7
Lennan, Elaine
3197869c-1e29-4c7e-94cc-7dc896044216
Diez de los Rios de la Serna, Celia, Richardson, Alison and Lennan, Elaine
(2017)
Adherence to low molecular weight heparin treatment by patients with cancer who develop VTE.
Cancer Nursing Practice, 16 (4), .
(doi:10.7748/cnp.2017.e1379).
Abstract
Patients with cancer who are diagnosed with venous thromboembolism (VTE) are managed with low molecular weight heparin (enoxaparin), an established treatment. Those with incidental VTE are generally stable and can be treated as outpatients, and their knowledge and ability to self-administer injections contributes to treatment adherence. However, the limited, or absence of, signs and symptoms associated with incidental VTE can affect adherence. This article reports the results of an audit that examined patients’ understanding of VTE, and the information they receive from healthcare professionals to support self-management. The audit found there is a difference in adherence between patients with incidental VTE and those who have symptomatic events. Results demonstrate the need for written information and a clear management pathway.
Text
Pre-journal editor title change post-submission
- Accepted Manuscript
Text
Adherence to low molecular weight heparin treatment by patients PROOF (002)
- Proof
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 10 March 2017
Published date: 10 May 2017
Organisations:
Researcher Development
Identifiers
Local EPrints ID: 408080
URI: http://eprints.soton.ac.uk/id/eprint/408080
ISSN: 1475-4266
PURE UUID: 19f8a187-0fe0-4c1f-9205-ecfc32fa7bac
Catalogue record
Date deposited: 11 May 2017 01:05
Last modified: 16 Mar 2024 05:16
Export record
Altmetrics
Contributors
Author:
Celia Diez de los Rios de la Serna
Author:
Elaine Lennan
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
